CD 200 - A useful marker in chronic B lymphoprolipherative disorders.

Conclusions: CD200 has a great impact in diagnosing B- chronic lymphoproliferative disorders, especially when we want to determine the origin of a CD19, CD5 positive population and distinguish between CLL and MCL. CD 23 is a reliable marker in those cases, but, as we showed, CD23 might have a lower specificity than CD200 for CLL. We added CD200 in our panels in order to diagnose chronic lymphoproliferative disorders, not to replace CD 23, but to improve and save time in our diagnostic process. The high expression of CD200 in CLL and HCL could open the option for new- targeted therapy (anti-CD200). PMID: 31803290 [PubMed]
Source: Journal of Medicine and Life - Category: General Medicine Tags: J Med Life Source Type: research

Related Links:

Conclusion: CD200 could be of high value in distinguishing CLL, MCL, and atypical CLL. CD200 expression can also be of prognostic and therapeutic value in CLL cases. PMID: 30583344 [PubMed - in process]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
Conclusion: Long-term overall survival in HCL patients treated with sc Cld was excellent and comparable to studies using iv Cld. Despite the long follow-up, sc Cld had a curative potential and relapses requiring re-treatment were observed only in a minority of patients. Secondary malignancies were predominantly non-hematological. These data indicate that patients need to be followed carefully with a special focus on secondary malignancies.DisclosuresChalandon: Roche: Membership on an entity's Board of Directors or advisory committees, Other: Travel costs.
Source: Blood - Category: Hematology Authors: Tags: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma-Clinical Studies: Poster II Source Type: research
Background: BRCA1 and BCRA2 (breast cancer 1 and 2) are tumor suppressor genes involved in repair of DNA double-strand breaks. Loss of BRCA1/2 activity by (germline) mutations (mut) or downregulation (DR) of gene expression (GE) correlates with an increased risk of breast and ovarian cancer. Mut in or reduced GE of BRCA1/2 have also been implicated in some hematological malignancies, although data are so far scarce. Moreover, PARP1 inhibitors, known to induce synthetic lethality in tumors harboring BRCA1/2 mut were shown to affect FLT3(ITD)-positive AML (acute myeloid leukemia) cells.Aims: Investigation of BRCA1/2 mut and ...
Source: Blood - Category: Hematology Authors: Tags: 603. Oncogenes and Tumor Suppressors: Poster I Source Type: research
This article summarizes the milestones in the deve lopment of moxetumomab pasudotox leading to this first approval for the treatment of adults with relapsed or refractory hairy cell leukaemia who received at least two prior systemic therapies, including treatment with a purine nucleoside analogue. Development of moxetumomab pasudotox for non-Hodgkin ’s lymphoma, chronic lymphocytic leukaemia and precursor cell lymphoblastic leukaemia/lymphoma was discontinued.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
AbstractHairy cell leukemia (HCL) is a rare and indolent mature B cell neoplasm. Most patients with HCL have excellent response to purine analogs and BRAF inhibitors. Therefore, it is clinically important to identify and differentiate HCL from other B cell neoplasms. HCL is predominantly found in the peripheral blood, bone marrow, or spleen. HCL presenting initially or solely in unusual sites is extremely rare (approximately ten or fewer). We hereby report a unique case of HCL presenting as vertebral osteolytic and epidural mass lesions without bone marrow, spleen, or peripheral blood involvement. The patient was a 53-year...
Source: Journal of Hematopathology - Category: Pathology Source Type: research
Symptomatic splenomegaly is a debilitating complication commonly observed in hematologic malignancies and disorders, including chronic lymphocytic leukemia (CLL), myelofibrosis (MF), myeloid metaplasia, lymphoma, prolymphocytic leukemia (PLL), and hairy cell leukemia (HCL). In the US, splenomegaly due to these conditions represents up to 27% of all splenomegaly cases, while common benign causes include liver disease, infection, and congestive splenomegaly.[1] Manifestations of symptomatic splenomegaly include mechanical discomfort, tenderness in the left upper quadrant, early satiety, gastric compression, abdominal bloatin...
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: General and Supportive Care Source Type: research
Studies of occupational exposure to Glyphosate report increased risks for non-Hodgkin Lymphoma, Multiple Myeloma, Hairy Cell Leukemia, and Chronic Lymphocytic Leukemia
Source: Disabled World - Category: Disability Tags: Warnings - Alerts & Advisories Source Type: news
Studies of occupational exposure to Glyphosate report increased risks for non-Hodgkin Lymphoma, Multiple Myeloma, Hairy Cell Leukemia, and Chronic Lymphocytic Leukemia
Source: Disabled World - Category: Disability Tags: Warnings - Advisories Source Type: news
The World Health Organization classification of non‐Hodgkin lymphoma (NHL) was introduced in 2001. However, its incorporation into clinical practice is not well‐described. We studied the distribution of NHL subtypes in adults diagnosed from 1998 to 2011, evaluated time trends, geo‐demographic correlates, and changes in 5‐year overall survival (OS). We obtained data prospectively collected by the National Cancer Data Base, which covers 70% of US cancer cases. There were 596,476 patients diagnosed with NHL. The major subtypes were diffuse large B‐cell (32.5%), chronic lymphocytic leukemia/small lymphocytic lymphoma...
Source: American Journal of Hematology - Category: Hematology Authors: Tags: Research Article Source Type: research
Chimeric antigen receptors (CARs) are hybrid proteins that have antibody binding fragments fused to protein signaling domains that activate T cells. The antibody binding fragments allow the CAR to recognize specific cell types, thereby activating the T cell through the protein signalling domain. Once activated, the T cells selectively eliminate the cells which they recognize. By engineering a T cell to express CARs with antibody binding fragments which are specific for cell surface proteins that are associated with diseased cells, it is possible to treat the disease. This is a promising new therapeutic approach known as ad...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
More News: Allergy & Immunology | Bone Marrow Aspiration and Biopsy | Cancer | Cancer & Oncology | Chronic Leukemia | Emergency Medicine | General Medicine | Hairy Cell Leukemia | Hematology | Leukemia | Lymphoma | Stem Cell Therapy | Stem Cells